Shares of NovoCure (NASDAQ:NVCR) soared nearly 6% in pre-market trading on Tuesday, following the company's third quarter earnings report that topped Wall Street expectations.
The oncology company reported a quarterly loss of $0.28 per share, narrower than the $0.33 per share loss that analysts had anticipated. Revenue for the quarter came in at $155.09 million, beating the consensus estimate of $143.95 million and representing a 21.8% increase from the same period last year.
The strong quarterly results were driven by continued adoption of NovoCure's Tumor Treating Fields therapy for various cancer types. The company highlighted increasing demand for its products used to treat malignant pleural mesothelioma and non-small cell lung cancer.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。